Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naïve patients: The VESD study

HIV Clinical Trials

Volumn 6, Issue 6, 2005, Pages 320-328

  Santos, Jesús ^a   Palacios, R ^a   Lopez M ^j   Galvez M C ^g   Lozano, F ⁿ   de la Torre, J ^b   Rios M J ^o   Lopez Cortes L F ^m   Rivero, A ^l   Torres Tortosa, M ^p   Marquez M ^a   del Arco, A ^b   Nuno E ^c   Fernandez S ^c   Onate F ^d   Grana, A ^e   Salgado, F ^e   Fernandez A ^f   Diez F ^h   Fernandez M ^h   Gutierrez Rave M ⁱ   Pasquau, J ^j   Lopez Ruz M A ^j   Martinez N M ^k   Hernandez Quero J ^k   Morales, D ^o   Pena D ^q   Perez M ^q   Vergara, A ^r   Terron A ^s   more..

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL COSTA DEL SOL   (Spain)

^c Especialidad en Oftalmología Hospital Comarcal de la Axarquía Vélez Málaga Málaga   (Spain)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^e Hospital de la Serranía   (Spain)

^f Hospital Comarcal de Melilla   (Spain)

^g HOSPITAL TORRECÁRDENAS   (Spain)

^h HOSPITAL DE PONIENTE   (Spain)

ⁱ Hospital de Santa Ana   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^k HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^l HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^m HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^o HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^p HOSPITAL PUNTA DE EUROPA   (Spain)

^q Hospital La Línea de la Concepción   (Spain)

^r HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

^s HOSPITAL DE JEREZ   (Spain)

more..

Author keywords

HAART; Na ve patients; Once daily antiretroviral therapy

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; POLYNEUROPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RASH; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD;

ADMINISTRATION, ORAL; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DIDANOSINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; OXAZINES; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; QUALITY OF LIFE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; STATISTICS, NONPARAMETRIC;

EID: 33644759713     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/1XAE-BB0W-QN5R-AJGJ     Document Type: Article

References (28)

1. Powderly WG. Sorting through confusing messages: the art of HAART. J Acquir Immune Defic Syndr. 2002;31:S3-S9.
2. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001;15:1369-1377.
3. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
4. Moyle G. Once-daily therapy: less is more. Int J STD AIDS. 2003;14(suppl 1):1-5.
5. Maggiolo F, Ripamonti D, Suter F. Once-a-day HAART: dream or reality? HIV Clin Trials. 2003;4:193-201.
6. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:251-265.
7. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41:681-690.
8. Knobel H, Alonso J, Casado JL, et al. GEEMA Study Group Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS. 2002;16:605-613.
9. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997;6:481-493.
10. Cañas EJ, García FJ, Andérica G. Epidemiología de la infección por el VIH y sida. In: Pachón J, Pujol E, Rivero A. La infección por el VIH. Guía práctica. 20 ed. Sevilla: SAEI; 2003:37-54.
11. Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS. 2002;16:53-61.
12. Friedl AC, Ledergerber B, Flepp M, et al. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study. AIDS. 2001;15:1793-1800.
13. Yazdanpanah Y, Sissoko D, Egger M, Mouton Y, Zwahlen M, Chene G. Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials. Br Med J. 2004;328:249-256.
14. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865-1873.
15. Lucas GM, Chaisson RE, Moore RD. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. AIDS. 2001;15:1679-1686.
16. Gallant JE, Staszewski S, Pozniak AL, et al. 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
17. Saag MS, Cahn P, Raffi F, et al. FTC-301 Study Team. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA. 2004;292:180-189.
18. Maggiolo F, Migliorino M, Maserati R, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Once Study Group. Antivir Ther. 2001;6:249-253.
19. Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir Ther. 2003;8:339-346.
20. Landman R, Schiemann R, Thiam S, et al. Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS. 2003;17:1017-1022.
21. Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Sereni D. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis. 2000; 182:599-602.
22. Arribas JR, Pulido F, Miro JM, et al. High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients) and the EfaVIP Cohort Study Group. AIDS. 2002;16:1554-1556.
23. Pulido F, Arribas JR, Miro J, et al. The EfaVIP Cohort Study Group clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 Study). J Acquir Immune Defic Syndr. 2004;35:343-350.
24. Santos J, Palacios R, Ruiz J, González M, Márquez M. Study of patients diagnosed with advanced HIV in the HAART era. OMEGA Cohort. Int J STD AIDS. 2005;16:252-255.
25. Perez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials. 2002;3:279-286.
26. Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol. 2001;51:213-217.
27. Reynolds NR, Testa MA, Marc LG, et al. Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study. AIDS Behav. 2004;8:141-150.
28. Moyle G. The assessing patients' preferred treatments (APPT-1) study. Int J STD AIDS. 2003;14(suppl 1):34-36.